Compugen Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Sales 2024 * | 37.9M 14.04B 3.16B | Sales 2025 * | 35.29M 13.07B 2.94B | Capitalization | 189M 69.98B 15.73B |
---|---|---|---|---|---|
Net income 2024 * | -13M -4.82B -1.08B | Net income 2025 * | -29M -10.74B -2.41B | EV / Sales 2024 * | 4.98 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.35 x |
P/E ratio 2024 * |
-16.2
x | P/E ratio 2025 * |
-7.81
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01/02/01 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01/22/01 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 02/17/02 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11/18/11 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11/18/11 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |